News Agency
The Times

Inmagene's anti-OX40 mAb demonstrated an extended half-life and a favorable safety profile in a Phase I study

  • Written by PR Newswire
  • IMG-007 has the potential to provide Q12W or less frequent dosing based on an extended half-life
  • IMG-007 has demonstrated a favorable safety profile, consistent with a silenced ADCC function via bioengineering
  • IMG-007 is being evaluated in two global proof-of-concept trials 

SAN DIEGO, Aug. 18, 2023 /PRNewswire/ -- Inmagene...

Read more: Inmagene's anti-OX40 mAb demonstrated an extended half-life and a favorable safety profile in a...

How Can Businesses Reduce the Risk of Commercial Litigation?

Commercial disputes often begin with a misunderstanding, an unclear contract or a delayed response to a growing problem. Seeking early advice from Litigation Lawyers Sydney with PCL lawyers can help businesses trust and identify legal risks, clarify obligations and create a strategy... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion